Latest Hotspot

Quell Therapeutics Advances CAR-Treg Therapy QEL-001 to Efficacy Phase in Liver Transplant Trial

13 June 2024
3 min read

Quell Therapeutics Ltd, a pioneering company in engineered T-regulatory cell treatments for severe immune-mediated diseases, is moving forward with QEL-001, their autologous engineered CAR-Treg cell therapy, into the efficacy phase of the LIBERATE Phase 1/2 trial for patients undergoing liver transplants. This progression comes after the successful administration in the initial safety phase and the subsequent approval by the trial's independent Data Safety and Monitoring Board, based on the review of clinical results.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

At the American Transplant Congress in Philadelphia, PA, USA, Professor Alberto Sánchez-Fueyo, a Hepatology Professor and Academic Director of the Institute of Liver Studies at Kings College London, as well as co-founder of Quell, shared updates on the LIBERATE study. 

The preliminary findings advocate for continued research into QEL-001 CAR-Treg therapy for liver transplant patients with HLA-A2 mismatches. The aim is to promote operational tolerance and mitigate the adverse effects linked to immunosuppressive therapy.

Quell is now moving forward with an efficacy cohort to evaluate QEL-001 in liver transplant patients. This phase will measure tolerance induction at two and 12 months post complete cessation of IS therapy. The outcomes at two months are anticipated to be strong indicators of sustained operational tolerance.

Luke Devey, the Chief Medical Officer at Quell Therapeutics, remarked, "Entering the next stage of clinical trials with QEL-001 in liver transplantation is very promising. This trial is crucial for liver transplant recipients who otherwise face lifelong systemic immunosuppression with significant side effects, including higher risks of malignancies, infections, and renal failure, all of which severely affect their quality of life."

QEL-001 represents a pioneering, antigen-specific CAR-Treg cell therapy, utilizing Quell’s advanced multi-modular engineered Treg platform. The therapy encompasses three proprietary components: a chimeric antigen receptor for tissue targeting, the Foxp3 Phenotype Lock™ module, and a safety switch. The QEL-001 CAR targets HLA-A2, directing its action to the transplanted organ site in HLA-A2 mismatched liver transplant recipients.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of June 13, 2024, there are 6 investigational drugs for the HLA-A2 target, including 9 indications, 8 R&D institutions involved, with related clinical trials reaching 4, and as many as 8315 patents.

QEL-001 targets HLA-A2 and is intended for the treatment of immune system diseases and digestive system disorders. The active indications for QEL-001 include liver function failure and liver transplant rejection. As of the latest available information, the drug has reached Phase 1/2 of clinical development.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

Virion Therapeutics Reports Promising Phase 1b Results for HBV Treatment at EASL Congress
Latest Hotspot
3 min read
Virion Therapeutics Reports Promising Phase 1b Results for HBV Treatment at EASL Congress
12 June 2024
Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.
Read →
FDA Greenlights Phase II/III Trial of KPG-121 Coupled with Abiraterone for Initial Therapy in mCRPC
Latest Hotspot
3 min read
FDA Greenlights Phase II/III Trial of KPG-121 Coupled with Abiraterone for Initial Therapy in mCRPC
12 June 2024
Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.
Read →
AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma, Advancing Oncology Pipeline
Latest Hotspot
3 min read
AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma, Advancing Oncology Pipeline
12 June 2024
AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 12
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 12
12 June 2024
Jun 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.